Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

8.570 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75
Open 8.570
Bid (Size) 7.980 (100)
Ask (Size) 8.740 (100)
Prev. Close 8.570
Today's Range 8.570 - 8.570
52wk Range 7.210 - 20.46
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 22, 2026) - Kahn Swick & Foti, LLC ("KSF")... 
Via Newsfile
Topics Lawsuit

Performance

YTD
-52.1%
-52.1%
1 Month
+5.2%
+5.2%
3 Month
-36.9%
-36.9%
6 Month
-56.9%
-56.9%
1 Year
-52.0%
-52.0%

More News

Read More
News headline image
INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
Via MarketBeat
Topics Intellectual Property
News headline image
ADMA Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages ADMA Investors With Losses to Contact the Firm
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ADMA Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages ADMA Investors With Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Via Newsfile
Topics Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. (ADMA) Securities Fraud Class Action Lawsuit Filed; August 10, 2026, Lead Plaintiff Deadline
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ADMA Biologics, Inc. (ADMA) Securities Fraud Class Action Lawsuit Filed; August 10, 2026, Lead Plaintiff Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Via Newsfile
Topics Lawsuit
News headline image
Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing
From Berger Montague
Via GlobeNewswire
News headline image
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Via Newsfile
Topics Lawsuit
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. (ADMA) Investors: August 10, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Via Newsfile
Topics Lawsuit
News headline image
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Via Newsfile
Topics Lawsuit

Frequently Asked Questions

Is ADMA Biologics Inc - Common Stock publicly traded?
Yes, ADMA Biologics Inc - Common Stock is publicly traded.
What exchange does ADMA Biologics Inc - Common Stock trade on?
ADMA Biologics Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ADMA Biologics Inc - Common Stock?
The ticker symbol for ADMA Biologics Inc - Common Stock is ADMA on the Nasdaq Stock Market
What is the current price of ADMA Biologics Inc - Common Stock?
The current price of ADMA Biologics Inc - Common Stock is 8.570
When was ADMA Biologics Inc - Common Stock last traded?
The last trade of ADMA Biologics Inc - Common Stock was at 06/22/26 04:00 PM ET
What is the market capitalization of ADMA Biologics Inc - Common Stock?
The market capitalization of ADMA Biologics Inc - Common Stock is 1.68B
How many shares of ADMA Biologics Inc - Common Stock are outstanding?
ADMA Biologics Inc - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.